Current and Emerging Targets in Immunotherapy for Osteosarcoma

Overview

Journal J Oncol

Specialty Oncology

Date 2019 Jan 30

PMID 30693030

Citations 61

Authors

Shinji Miwa

Toshiharu Shirai

Norio Yamamoto

Katsuhiro Hayashi

Akihiko Takeuchi

Kentaro Igarashi

Hiroyuki Tsuchiya

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.

Citing Articles

Identification and functional characterization of T-cell exhaustion-associated lncRNA AL031775.1 in osteosarcoma: a novel therapeutic target.

Wang Y, Yuan J, Guo K, Zhang Z, Zhu J, Arya S Front Immunol. 2025; 16:1517971.

PMID: 40066455 PMC: 11891247. DOI: 10.3389/fimmu.2025.1517971.

Naringenin induces ferroptosis in osteosarcoma cells through the STAT3-MGST2 signaling pathway.

Li Y, Bai X J Bone Oncol. 2025; 50():100657.

PMID: 39835176 PMC: 11743371. DOI: 10.1016/j.jbo.2024.100657.

New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing.

Zheng S, Luo M, Huang H, Huang X, Peng Z, Zheng S Cell Commun Signal. 2024; 22(1):592.

PMID: 39696352 PMC: 11657588. DOI: 10.1186/s12964-024-01989-w.

CircZMYM2 plays a pivotal role in osteosarcoma by regulating the translation of and .

Li F, Wei J, Ren X, Hao Y, Tian S, Li L Heliyon. 2024; 10(22):e37744.

PMID: 39624324 PMC: 11609666. DOI: 10.1016/j.heliyon.2024.e37744.

CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis.

Ko Y, Park S, Park J, Kim J, Kang H, Lee J Cells. 2024; 13(22).

PMID: 39594611 PMC: 11592588. DOI: 10.3390/cells13221862.

References

Eilber F, Townsend C, Morton D . Osteosarcoma. Results of treatment employing adjuvant immunotherapy. Clin Orthop Relat Res. 1975; (111):94-100. View

Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K . Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res. 2001; 19(3):346-51. DOI: 10.1016/S0736-0266(00)90031-7. View

Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Yanik G, Levine J . Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001; 61(23):8513-9. View

Bielack S, Kempf-Bielack B, Delling G, Exner G, Flege S, Helmke K . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3):776-90. DOI: 10.1200/JCO.2002.20.3.776. View

Schumacher T . T-cell-receptor gene therapy. Nat Rev Immunol. 2002; 2(7):512-9. DOI: 10.1038/nri841. View

Bukowski R, Tendler C, Cutler D, Rose E, Laughlin M, Statkevich P . Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 2002; 95(2):389-96. DOI: 10.1002/cncr.10663. View

Tsuchiya H, Kanazawa Y, Abdel-Wanis M, Asada N, Abe S, Isu K . Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol. 2002; 20(16):3470-7. DOI: 10.1200/JCO.2002.11.028. View

Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B . Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003; 21(10):2011-8. DOI: 10.1200/JCO.2003.08.132. View

Morgan R, Dudley M, Yu Y, Zheng Z, Robbins P, Theoret M . High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003; 171(6):3287-95. PMC: 2248799. DOI: 10.4049/jimmunol.171.6.3287. View

10.

Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K . Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 2004; 64(15):5442-8. DOI: 10.1158/0008-5472.CAN-04-0522. View

11.

Zhao Y, Zheng Z, Robbins P, Khong H, Rosenberg S, Morgan R . Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005; 174(7):4415-23. PMC: 2174604. DOI: 10.4049/jimmunol.174.7.4415. View

12.

Schwinger W, Klass V, Benesch M, Lackner H, Dornbusch H, Sovinz P . Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol. 2005; 16(7):1199-206. DOI: 10.1093/annonc/mdi226. View

13.

Hughes M, Yu Y, Dudley M, Zheng Z, Robbins P, Li Y . Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005; 16(4):457-72. PMC: 1476695. DOI: 10.1089/hum.2005.16.457. View

14.

Lascelles B, Dernell W, Correa M, Lafferty M, Devitt C, Kuntz C . Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005; 12(12):1073-83. DOI: 10.1245/ASO.2005.01.011. View

15.

Kleinerman E, Jia S, Griffin J, Seibel N, Benjamin R, Jaffe N . Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992; 10(8):1310-6. DOI: 10.1200/JCO.1992.10.8.1310. View

16.

de Visser K, Eichten A, Coussens L . Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006; 6(1):24-37. DOI: 10.1038/nrc1782. View

17.

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G . Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006; 32(6):423-36. DOI: 10.1016/j.ctrv.2006.05.005. View

18.

Jeys L, Grimer R, Carter S, Tillman R, Abudu A . Post operative infection and increased survival in osteosarcoma patients: are they associated?. Ann Surg Oncol. 2007; 14(10):2887-95. DOI: 10.1245/s10434-007-9483-8. View

19.

Coley W . II. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891; 14(3):199-220. PMC: 1428624. DOI: 10.1097/00000658-189112000-00015. View

20.

Meyers P, Schwartz C, Krailo M, Healey J, Bernstein M, Betcher D . Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4):633-8. DOI: 10.1200/JCO.2008.14.0095. View